Payment overview · 2025
General Payments
$289.57
24 reported records · 3 companies
Healthcare provider profile · identity verified
Merle Ray Holsopple, MD
Allopathic & Osteopathic Physicians|Family Medicine · MONTGOMERY, IN · NPI 1538137294
Verified facts
What the public records show
CMS Open Payments records show Merle Ray Holsopple, MD received $289.57 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 88.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $256.14 | 88.5% | 22 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $19.84 | 6.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.59 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $289.57 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $203.49 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $201.67 | 18 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.38 | 3 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 482 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 429 | 70 |
| Furosemide | Furosemide | 416 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 381 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 365 | 54 |
| Potassium Chloride | Potassium Chloride | 338 | 56 |
| Lisinopril | Lisinopril | 320 | 61 |
| Gabapentin | Gabapentin | 314 | 53 |
| Omeprazole | Omeprazole | 241 | 51 |
| Alprazolam | Alprazolam | 209 | 44 |
| Metformin Hcl | Metformin Hcl | 204 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 179 | 37 |
| Carvedilol | Carvedilol | 177 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 166 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 44 |
| Simvastatin | Simvastatin | 150 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 139 | 27 |
| Allopurinol | Allopurinol | 124 | 23 |
| Tramadol Hcl | Tramadol Hcl | 121 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 34 |
| Ibuprofen | Ibuprofen | 119 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 27 |
| Eliquis | Apixaban | 108 | 19 |
| Memantine Hcl | Memantine Hcl | 107 | 17 |
| Levetiracetam | Levetiracetam | 106 | suppressed |
| Baclofen | Baclofen | 100 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 95 | suppressed |
| Losartan Potassium | Losartan Potassium | 93 | 17 |
| Risperidone | Risperidone | 93 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 92 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 87 | 13 |
| Lithium Carbonate | Lithium Carbonate | 87 | suppressed |
| Lamotrigine | Lamotrigine | 86 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 85 | 15 |
| Montelukast Sodium | Montelukast Sodium | 84 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 83 | suppressed |
| Bupropion Xl | Bupropion Hcl | 82 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 22 |
| Lorazepam | Lorazepam | 76 | 15 |
| Spironolactone | Spironolactone | 76 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 75 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 75 | 13 |
| Atenolol | Atenolol | 73 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 73 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 15 |
| Aripiprazole | Aripiprazole | 65 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 19 |
| Mounjaro | Tirzepatide | 61 | 11 |
| Prednisone | Prednisone | 61 | 46 |
| Xarelto | Rivaroxaban | 61 | suppressed |
| Eszopiclone | Eszopiclone | 60 | 11 |
| Azithromycin | Azithromycin | 59 | 51 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 12 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 56 | 12 |
| Celecoxib | Celecoxib | 53 | 16 |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Topiramate | Topiramate | 51 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 50 | suppressed |
| Clonazepam | Clonazepam | 49 | suppressed |
| Levofloxacin | Levofloxacin | 49 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 48 | suppressed |
| Famotidine | Famotidine | 47 | suppressed |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Diazepam | Diazepam | 45 | suppressed |
| Estradiol | Estradiol | 45 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Rexulti | Brexpiprazole | 44 | suppressed |
| Olanzapine | Olanzapine | 43 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Bumetanide | Bumetanide | 42 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Linzess | Linaclotide | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 42 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 12 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Temazepam | Temazepam | 40 | suppressed |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Nystatin | Nystatin | 38 | 16 |
| Prazosin Hcl | Prazosin Hcl | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Sucralfate | Sucralfate | 36 | 11 |
| Finasteride | Finasteride | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 16 |
| Vraylar | Cariprazine Hcl | 33 | suppressed |
| Fluconazole | Fluconazole | 32 | 22 |
| Lithium Carbonate Er | Lithium Carbonate | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | 11 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 31 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Meloxicam | Meloxicam | 29 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 17 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Nyamyc | Nystatin | 28 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 19 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 19 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | 11 |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Pindolol | Pindolol | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Alprazolam Er | Alprazolam | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $289.57 · 24 records | ABBVIE INC. | Auvelity, QULIPTA, Senza, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error